BRPI0512944A - agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 - Google Patents

agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1

Info

Publication number
BRPI0512944A
BRPI0512944A BRPI0512944-3A BRPI0512944A BRPI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A BR PI0512944 A BRPI0512944 A BR PI0512944A
Authority
BR
Brazil
Prior art keywords
treatment
hmgb1
therapeutic agents
related conditions
nucleic acid
Prior art date
Application number
BRPI0512944-3A
Other languages
English (en)
Inventor
Domenico G Barone
Marco E Bianchi
Enrico M Bucci
Silvano Fumero
Margherita Valente
Roberto Sapio
Domenica Musumeci
Original Assignee
Creabilis Therapeutics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0512944(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Creabilis Therapeutics Spa filed Critical Creabilis Therapeutics Spa
Publication of BRPI0512944A publication Critical patent/BRPI0512944A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

AGENTES TERAPêUTICOS PARA O TRATAMENTO DE PATOLOGIAS RELACIONADAS COM HMGB1. A presente invenção refere-se ao uso de moléculas de ácido nucléico de filamento duplo sintéticas ou análogas de ácido nucléico com um estrutura em forma dobrada para a prevenção e tratamento de patologias induzidas direta ou indiretamente pela proteína HMGB1.
BRPI0512944-3A 2004-07-02 2005-07-04 agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1 BRPI0512944A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26
PCT/EP2005/007198 WO2006002971A2 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies

Publications (1)

Publication Number Publication Date
BRPI0512944A true BRPI0512944A (pt) 2008-04-15

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512944-3A BRPI0512944A (pt) 2004-07-02 2005-07-04 agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1

Country Status (14)

Country Link
US (1) US20080305073A1 (pt)
EP (1) EP1768677B1 (pt)
JP (1) JP2008504335A (pt)
AT (1) ATE399014T1 (pt)
AU (1) AU2005259381A1 (pt)
BR (1) BRPI0512944A (pt)
CA (1) CA2572519A1 (pt)
DE (1) DE602005007746D1 (pt)
DK (1) DK1768677T3 (pt)
ES (1) ES2306195T3 (pt)
IL (1) IL179828A0 (pt)
PL (1) PL1768677T3 (pt)
PT (1) PT1768677E (pt)
WO (1) WO2006002971A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ，インコーポレイティド Ｒａｇｅ融合タンパク質及びその使用方法
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
NZ569545A (en) * 2006-02-09 2011-11-25 Transtech Pharma Inc Rage fusion proteins and methods of use for treating inflammation
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
CA2669969A1 (en) * 2006-11-17 2008-05-22 Clinical Gene Networks Ab Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb3, hsdl2 and/or ldb2
WO2009140676A2 (en) * 2008-05-16 2009-11-19 Immune Disease Institute, Inc. Compositions and methods for inhibition of retroviruses
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
JP5710482B2 (ja) 2008-09-11 2015-04-30 アンスティテュ・パストゥール Ｈｍｇｂ１依存型誘発のｈｉｖ−１複製および持続の調節によるヒト免疫不全ウイルス感染の監視および阻害
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
PL2381964T3 (pl) 2008-12-22 2014-11-28 Creabilis S A Synteza polimerowych koniugatów związków indazolokarbazolowych
KR20110139292A (ko) 2009-04-20 2011-12-28 화이자 인코포레이티드 단백질 글리코실화의 제어 및 그와 관련된 조성물 및 방법
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
JP5686814B2 (ja) 2010-09-17 2015-03-18 独立行政法人科学技術振興機構 Ｈｍｇｂタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
WO2013116590A1 (en) * 2012-02-01 2013-08-08 George Miller Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトｈｍｇｂ１結合剤およびヒトｈｍｇｂ１除去装置
EP3600440A1 (en) 2017-03-20 2020-02-05 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
EP3621657A1 (en) 2017-05-10 2020-03-18 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
WO2023250249A1 (en) * 2022-06-23 2023-12-28 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009158A1 (en) * 1992-10-14 1994-04-28 University Research Corporation Method for selecting nucleic acids on the basis of structure
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EP1569684A4 (en) * 2002-11-20 2006-08-02 Critical Therapeutics Inc USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS

Also Published As

Publication number Publication date
DE602005007746D1 (de) 2008-08-07
US20080305073A1 (en) 2008-12-11
JP2008504335A (ja) 2008-02-14
CA2572519A1 (en) 2006-01-12
AU2005259381A1 (en) 2006-01-12
EP1768677A2 (en) 2007-04-04
IL179828A0 (en) 2008-03-20
ES2306195T3 (es) 2008-11-01
PT1768677E (pt) 2008-10-06
DK1768677T3 (da) 2008-10-20
WO2006002971A3 (en) 2006-04-20
PL1768677T3 (pl) 2009-01-30
WO2006002971A2 (en) 2006-01-12
ATE399014T1 (de) 2008-07-15
EP1768677B1 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
BRPI0512944A (pt) agentes terapêuticos para o tratamento de patologias relacionadas com hmgb1
ATE476193T1 (de) Immunstimulatorisches verfahren
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DE602006019838D1 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE499088T1 (de) Glp-1-fc fusionsprotein-formulierung
ATE447551T1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE502006004066D1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
EA201370208A1 (ru) Формы рифаксимина и их применение
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
ECSP066559A (pt)
TW200509892A (en) Novel aminobenzophenone compounds
BRPI0722054A2 (pt) Composição, kit, e métodos para diminuir um efeito colateral de tratamento com um inibidor da calcineurina, para aumentar um efeito terapêutico de um inibidor da calcineurina e para mudar a concentração de tacrolimus ou um análogo de tacrolimus em um compartimento fisiológico.
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
EA201100297A1 (ru) Биотесты на белок polyq
DE602007007618D1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ATE474574T1 (de) Imidazoazephinonverbindungen
FR2905600B1 (fr) Traitement des vertiges par l'acetyl-l-leucine.
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
NI201000067A (es) Intermediarios de gsm.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.